Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success

Verastem $VSTM is getting its proverbial second chance.

Once battered, bruised and left on the ropes after the complete failure of the initial strategy mapped by Christoph Westphal, the executive team at Verastem snapped up a tarnished star as Infinity happily handed off its perfectly approvable — but commercially unexciting — PI3K drug duvelisib for exactly nothing up front.